Immunohistochemical selection of biomarkers for tumor-targeted image-guided surgery of myxofibrosarcoma.
| Title: | Immunohistochemical selection of biomarkers for tumor-targeted image-guided surgery of myxofibrosarcoma. |
|---|---|
| Authors: | de Gooyer JM; Department of Radiology and Nuclear Medicine, Radboud university medical center, Nijmegen, the Netherlands. jan-marie.gooyer@radboudumc.nl.; Department of Surgery, Radboud university medical center, Nijmegen, the Netherlands. jan-marie.gooyer@radboudumc.nl.; Versleijen-Jonkers YMH; Department of Medical Oncology, Radboud university medical center, Nijmegen, the Netherlands.; Hillebrandt-Roeffen MHS; Department of Medical Oncology, Radboud university medical center, Nijmegen, the Netherlands.; Frielink C; Department of Radiology and Nuclear Medicine, Radboud university medical center, Nijmegen, the Netherlands.; Desar IME; Department of Medical Oncology, Radboud university medical center, Nijmegen, the Netherlands.; de Wilt JHW; Department of Surgery, Radboud university medical center, Nijmegen, the Netherlands.; Flucke U; Department of Pathology, Radboud university medical center, Nijmegen, the Netherlands.; Rijpkema M; Department of Radiology and Nuclear Medicine, Radboud university medical center, Nijmegen, the Netherlands. |
| Source: | Scientific reports [Sci Rep] 2020 Feb 19; Vol. 10 (1), pp. 2915. Date of Electronic Publication: 2020 Feb 19. |
| Publication Type: | Journal Article |
| Language: | English |
| Journal Info: | Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: London : Nature Publishing Group, copyright 2011- |
| MeSH Terms: | Surgery, Computer-Assisted*; Biomarkers, Tumor/*metabolism ; Fibrosarcoma/*metabolism ; Fibrosarcoma/*surgery; Fascia/pathology ; Fibrosarcoma/pathology ; Muscles/pathology ; Neoplasm Proteins/metabolism ; Humans ; Immunohistochemistry ; Preoperative Care |
| Abstract: | Myxofibrosarcoma(MFS) is the most common soft tissue sarcoma(STS) in elderly patients. Surgical resection remains the main treatment modality but tumor borders can be difficult to delineate with conventional clinical methods. Incomplete resections are a common problem and local recurrence remains a clinical issue. A technique that has shown great potential in improving surgical treatment of solid tumors is tumor targeted imaging and image-guided surgery with near-infrared fluorescence. To facilitate this technique, it is essential to identify a biomarker that is highly and homogenously expressed on tumor cells, while being absent on healthy non-malignant tissue. The purpose of this study was to identify suitable molecular targets for tumor-targeted imaging of myxofibrosarcoma. Ten potential molecular targets for tumor targeted imaging were investigated with immunohistochemical analysis in myxofibrosarcoma tissue (n = 34). Results were quantified according to the immunoreactive score(IRS). Moderate expression rates were found for uPAR, PDGFRa and EMA/MUC1. High expression rates of VEGF and TEM1 were seen. Strong expression was most common for TEM1 (88.2%). These results confirms that TEM1 is a suitable target for tumor-targeted imaging of myxofibrosarcoma. Keywords Image-guided surgery; Immunohistochemistry; Molecular imaging; Myxofibrosarcoma; Soft tissue sarcoma; Tumor endothelial marker 1(TEM1), Vascular endothelial growth factor (VEGF). |
| References: | Angervall, L., Kindblom, L. G. & Merck, C. Myxofibrosarcoma. A study of 30 cases. Acta pathologica et microbiologica Scandinavica. Section A, Pathology 85a, 127–140 (1977).; Fletcher, C. D. The evolving classification of soft tissue tumours: an update based on the new WHO classification. Histopathology 48, 3–12, https://doi.org/10.1111/j.1365-2559.2005.02284.x (2006). (PMID: 10.1111/j.1365-2559.2005.02284.x1635953216359532); Willems, S. M., Debiec-Rychter, M., Szuhai, K., Hogendoorn, P. C. & Sciot, R. Local recurrence of myxofibrosarcoma is associated with increase in tumour grade and cytogenetic aberrations, suggesting a multistep tumour progression model. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc 19, 407–416, https://doi.org/10.1038/modpathol.3800550 (2006). (PMID: 10.1038/modpathol.3800550); Mentzel, T. et al. Myxofibrosarcoma. Clinicopathologic analysis of 75 cases with emphasis on the low-grade variant. The American journal of surgical pathology 20, 391–405 (1996). (PMID: 10.1097/00000478-199604000-0000186048058604805); Look Hong, N. J. et al. Prognostic factors and outcomes of patients with myxofibrosarcoma. Annals of surgical oncology 20, 80–86, https://doi.org/10.1245/s10434-012-2572-3 (2013). (PMID: 10.1245/s10434-012-2572-32289059422890594); Huang, H. Y., Lal, P., Qin, J., Brennan, M. F. & Antonescu, C. R. Low-grade myxofibrosarcoma: a clinicopathologic analysis of 49 cases treated at a single institution with simultaneous assessment of the efficacy of 3-tier and 4-tier grading systems. Hum Pathol 35, 612–621 (2004). (PMID: 10.1016/j.humpath.2004.01.0161513893715138937); Haglund, K. E. et al. Recurrence patterns and survival for patients with intermediate- and high-grade myxofibrosarcoma. International journal of radiation oncology, biology, physics 82, 361–367, https://doi.org/10.1016/j.ijrobp.2010.08.042 (2012). (PMID: 10.1016/j.ijrobp.2010.08.0422095150420951504); Sanfilippo, R. et al. Myxofibrosarcoma: prognostic factors and survival in a series of patients treated at a single institution. Annals of surgical oncology 18, 720–725, https://doi.org/10.1245/s10434-010-1341-4 (2011). (PMID: 10.1245/s10434-010-1341-42087824520878245); Tsuchie, H. et al. Distant metastasis in patients with myxofibrosarcoma. Upsala journal of medical sciences 122, 190–193, https://doi.org/10.1080/03009734.2017.1356404 (2017). (PMID: 10.1080/03009734.2017.13564042881415228814152); Casali, P. G. et al. Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO 29, iv268–iv269, https://doi.org/10.1093/annonc/mdy321 (2018). (PMID: 10.1093/annonc/mdy321); Odei, B. et al. Predictors of Local Recurrence in Patients With Myxofibrosarcoma. American journal of clinical oncology 41, 827–831, https://doi.org/10.1097/coc.0000000000000382 (2018). (PMID: 10.1097/coc.00000000000003822864006428640064); Lefkowitz, R. A. et al. Myxofibrosarcoma: prevalence and diagnostic value of the “tail sign” on magnetic resonance imaging. Skeletal radiology 42, 809–818, https://doi.org/10.1007/s00256-012-1563-6 (2013). (PMID: 10.1007/s00256-012-1563-62331890723318907); Waters, B. et al. Low-grade myxofibrosarcoma: CT and MRI patterns in recurrent disease. AJR. American journal of roentgenology 188, W193–198, https://doi.org/10.2214/ajr.05.1130 (2007). (PMID: 10.2214/ajr.05.11301724222717242227); Ghazala, C. G. et al. Myxofibrosarcoma of the extremity and trunk: a multidisciplinary approach leads to good local rates of LOCAL control. The bone & joint journal 98-b, 1682–1688, https://doi.org/10.1302/0301-620x.98b12.37568 (2016). (PMID: 10.1302/0301-620x.98b12.37568); Yoo, H. J. et al. MR imaging of myxofibrosarcoma and undifferentiated sarcoma with emphasis on tail sign; diagnostic and prognostic value. European radiology 24, 1749–1757, https://doi.org/10.1007/s00330-014-3181-2 (2014). (PMID: 10.1007/s00330-014-3181-2); Vahrmeijer, A. L., Hutteman, M., van der Vorst, J. R., van de Velde, C. J. & Frangioni, J. V. Image-guided cancer surgery using near-infrared fluorescence. Nature reviews. Clinical oncology 10, 507–518, https://doi.org/10.1038/nrclinonc.2013.123 (2013). (PMID: 10.1038/nrclinonc.2013.12337550133755013); Hoogstins, C. E. et al. In Search for Optimal Targets for Intraoperative Fluorescence Imaging of Peritoneal Metastasis From Colorectal Cancer. Biomarkers in cancer 9, 1179299x17728254, https://doi.org/10.1177/1179299x17728254 (2017). (PMID: 10.1177/1179299x1772825455765395576539); Boogerd, L. S. et al. Biomarker expression in rectal cancer tissue before and after neoadjuvant therapy. Onco Targets Ther 11, 1655–1664, https://doi.org/10.2147/ott.S145473 (2018). (PMID: 10.2147/ott.S14547358706585870658); Boonstra, M. C. et al. Stromal Targets for Fluorescent-Guided Oncologic. Surgery. Frontiers in oncology 5, 254, https://doi.org/10.3389/fonc.2015.00254 (2015). (PMID: 10.3389/fonc.2015.00254); Boonstra, M. C. et al. Selecting Targets for Tumor Imaging: An Overview of Cancer-Associated Membrane Proteins. Biomarkers in cancer 8, 119–133, https://doi.org/10.4137/bic.S38542 (2016). (PMID: 10.4137/bic.S385422772165827721658); Boogerd, L. S. F. et al. Safety and effectiveness of SGM-101, a fluorescent antibody targeting carcinoembryonic antigen, for intraoperative detection of colorectal cancer: a dose-escalation pilot study. The lancet. Gastroenterology & hepatology 3, 181–191, doi:10.1016/s2468-1253(17)30395-3 (2018).; Terwisscha van Scheltinga, A. G. et al. Intraoperative near-infrared fluorescence tumor imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting antibodies. Journal of nuclear medicine: official publication, Society of Nuclear Medicine 52, 1778–1785, https://doi.org/10.2967/jnumed.111.092833 (2011). (PMID: 10.2967/jnumed.111.092833); Boogerd, L. S. F. et al. Fluorescence-guided tumor detection with a novel anti-EpCAM targeted antibody fragment: Preclinical validation. Surg Oncol 28, 1–8, https://doi.org/10.1016/j.suronc.2018.10.004 (2019). (PMID: 10.1016/j.suronc.2018.10.0043085188030851880); Chen, H. et al. MUC1 aptamer-based near-infrared fluorescence probes for tumor imaging. Molecular imaging and biology: MIB: the official publication of the Academy of Molecular Imaging 17, 38–48, https://doi.org/10.1007/s11307-014-0763-y (2015). (PMID: 10.1007/s11307-014-0763-y); Hekman, M. C. et al. Tumor-targeted Dual-modality Imaging to Improve Intraoperative Visualization of Clear Cell Renal Cell Carcinoma: A First in Man Study. Theranostics 8, 2161–2170, https://doi.org/10.7150/thno.23335 (2018). (PMID: 10.7150/thno.233352972107029721070); Li, C. et al. Development, optimization, and validation of novel anti-TEM1/CD248 affinity agent for optical imaging in cancer. Oncotarget 5, 6994–7012, https://doi.org/10.18632/oncotarget.2188 (2014). (PMID: 10.18632/oncotarget.21882505136525051365); Nishio, N. et al. Optimal Dosing Strategy for Fluorescence-Guided Surgery with Panitumumab-IRDye800CW in Head and Neck Cancer. Molecular imaging and biology: MIB: the official publication of the Academy of Molecular Imaging, https://doi.org/10.1007/s11307-019-01358-x (2019).; Skovgaard, D. et al. Safety, Dosimetry, and Tumor Detection Ability of (68)Ga-NOTA-AE105: First-in-Human Study of a Novel Radioligand for uPAR PET Imaging. Journal of nuclear medicine: official publication, Society of Nuclear Medicine 58, 379–386, https://doi.org/10.2967/jnumed.116.178970 (2017). (PMID: 10.2967/jnumed.116.178970); Dissoki, S., Abourbeh, G., Salnikov, O., Mishani, E. & Jacobson, O. PET molecular imaging of angiogenesis with a multiple tyrosine kinase receptor-targeted agent in a rat model of myocardial infarction. Molecular imaging and biology: MIB: the official publication of the Academy of Molecular Imaging 17, 222–230, https://doi.org/10.1007/s11307-014-0790-8 (2015). (PMID: 10.1007/s11307-014-0790-8); Specht, E. et al. Comparison of immunoreactive score, HER2/neu score and H score for the immunohistochemical evaluation of somatostatin receptors in bronchopulmonary neuroendocrine neoplasms. Histopathology 67, 368–377, https://doi.org/10.1111/his.12662 (2015). (PMID: 10.1111/his.126622564108225641082); Hoogstins, C. E. S. et al. Image-Guided Surgery in Patients with Pancreatic Cancer: First Results of a Clinical Trial Using SGM-101, a Novel Carcinoembryonic Antigen-Targeting, Near-Infrared Fluorescent Agent. Annals of surgical oncology 25, 3350–3357, https://doi.org/10.1245/s10434-018-6655-7 (2018). (PMID: 10.1245/s10434-018-6655-73005136930051369); Harlaar, N. J. et al. Molecular fluorescence-guided surgery of peritoneal carcinomatosis of colorectal origin: a single-centre feasibility study. The lancet. Gastroenterology & hepatology 1, 283–290, https://doi.org/10.1016/s2468-1253(16)30082-6 (2016). (PMID: 10.1016/s2468-1253(16)30082-6); Miller, S. E. et al. First-in-human intraoperative near-infrared fluorescence imaging of glioblastoma using cetuximab-IRDye800. Journal of neuro-oncology. https://doi.org/10.1007/s11060-018-2854-0 (2018). (PMID: 10.1007/s11060-018-2854-03053619530536195); Heitzer, E. et al. Expanded molecular profiling of myxofibrosarcoma reveals potentially actionable targets. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc 30, 1698–1709, https://doi.org/10.1038/modpathol.2017.94 (2017). (PMID: 10.1038/modpathol.2017.94); Scoccianti, G. et al. Soft tissue myxofibrosarcoma: A clinico-pathological analysis of a series of 75 patients with emphasis on the epithelioid variant. Journal of surgical oncology 114, 50–55, https://doi.org/10.1002/jso.24250 (2016). (PMID: 10.1002/jso.242502707619827076198); Forker, L. et al. The hypoxia marker CAIX is prognostic in the UK phase III VorteX-Biobank cohort: an important resource for translational research in soft tissue sarcoma. Br J Cancer 118, 698–704, https://doi.org/10.1038/bjc.2017.430 (2018). (PMID: 10.1038/bjc.2017.4302923557129235571); Mentzel, T. et al. The association between tumour progression and vascularity in myxofibrosarcoma and myxoid/round cell liposarcoma. Virchows Archiv: an international journal of pathology 438, 13–22 (2001). (PMID: 10.1007/s004280000327); Sato, O. et al. Expression of epidermal growth factor receptor, ERBB2 and KIT in adult soft tissue sarcomas: a clinicopathologic study of 281 cases. Cancer 103, 1881–1890, https://doi.org/10.1002/cncr.20986 (2005). (PMID: 10.1002/cncr.20986); van Oosten, M., Crane, L. M., Bart, J., van Leeuwen, F. W. & van Dam, G. M. Selecting Potential Targetable Biomarkers for Imaging Purposes in Colorectal Cancer Using TArget Selection Criteria (TASC): A Novel Target Identification Tool. Translational oncology 4, 71–82 (2011). (PMID: 10.1593/tlo.1022030696503069650); Tjalma, J. J. et al. Molecular Fluorescence Endoscopy Targeting Vascular Endothelial Growth Factor A for Improved Colorectal Polyp Detection. Journal of nuclear medicine: official publication, Society of Nuclear Medicine 57, 480–485, https://doi.org/10.2967/jnumed.115.166975 (2016). (PMID: 10.2967/jnumed.115.166975); Ferrara, N. & Davis-Smyth, T. The biology of vascular endothelial growth factor. Endocrine reviews 18, 4–25, https://doi.org/10.1210/edrv.18.1.0287 (1997). (PMID: 10.1210/edrv.18.1.028790347849034784); Folpe, A. L. “Hey!- Whatever Happened to Hemangiopericytoma and Fibrosarcoma?” An Update on Selected Conceptual Advances in Soft Tissue Pathology Which Have Occurred Over the Past 50 Years. Hum Pathol, https://doi.org/10.1016/j.humpath.2019.10.001 (2019).; Rouleau, C. et al. Endosialin protein expression and therapeutic target potential in human solid tumors: sarcoma versus carcinoma. Clinical cancer research: an official journal of the American Association for Cancer Research 14, 7223–7236, https://doi.org/10.1158/1078-0432.Ccr-08-0499 (2008). (PMID: 10.1158/1078-0432.Ccr-08-0499); Guo, Y. et al. Tumour endothelial marker 1/endosialin-mediated targeting of human sarcoma. European journal of cancer (Oxford, England: 1990) 90, 111–121, https://doi.org/10.1016/j.ejca.2017.10.035 (2018). (PMID: 10.1016/j.ejca.2017.10.035); Christian, S. et al. Endosialin (Tem1) is a marker of tumor-associated myofibroblasts and tumor vessel-associated mural cells. The American journal of pathology 172, 486–494, https://doi.org/10.2353/ajpath.2008.070623 (2008). (PMID: 10.2353/ajpath.2008.0706231818756518187565); Kiyohara, E. et al. Endosialin Expression in Metastatic Melanoma Tumor Microenvironment Vasculature: Potential Therapeutic Implications. Cancer microenvironment: official journal of the International Cancer Microenvironment Society 8, 111–118, https://doi.org/10.1007/s12307-015-0168-8 (2015). (PMID: 10.1007/s12307-015-0168-8); Simonavicius, N. et al. Endosialin (CD248) is a marker of tumor-associated pericytes in high-grade glioma. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc 21, 308–315, https://doi.org/10.1038/modpathol.3801006 (2008). (PMID: 10.1038/modpathol.3801006); Davies, G., Cunnick, G. H., Mansel, R. E., Mason, M. D. & Jiang, W. G. Levels of expression of endothelial markers specific to tumour-associated endothelial cells and their correlation with prognosis in patients with breast cancer. Clinical & experimental metastasis 21, 31–37 (2004). (PMID: 10.1023/B:CLIN.0000017168.83616.d0); Lange, S. E. et al. Development of 89Zr-Ontuxizumab for in vivo TEM-1/endosialin PET applications. Oncotarget 7, 13082–13092, https://doi.org/10.18632/oncotarget.7552 (2016). (PMID: 10.18632/oncotarget.75522690961526909615); O’Shannessy, D. J. et al. Endosialin and Associated Protein Expression in Soft Tissue Sarcomas: A Potential Target for Anti-Endosialin Therapeutic Strategies. Sarcoma 2016, 5213628, https://doi.org/10.1155/2016/5213628 (2016). (PMID: 10.1155/2016/52136282705713727057137); Teicher, B. A. CD248: A therapeutic target in cancer and fibrotic diseases. Oncotarget 10, 993–1009, https://doi.org/10.18632/oncotarget.26590 (2019). (PMID: 10.18632/oncotarget.265903084702730847027) |
| Substance Nomenclature: | 0 (Biomarkers, Tumor); 0 (Neoplasm Proteins) |
| Entry Date(s): | Date Created: 20200221 Date Completed: 20201112 Latest Revision: 20210218 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC7031512 |
| DOI: | 10.1038/s41598-020-59735-4 |
| PMID: | 32076024 |
| Database: | MEDLINE |
Journal Article